Figure 5. A second infusion of engineered TCR1045 cells also preferentially accumulates in PDA.
(A) Schematic of congenically distinct T cell infusions into same KPC recipients. Cyclophosphamide (Cy) was administered prior to the 1st infusion only.
(B) Circulating CD8 T cells prior to transfer (D0), 20 days following first infusion of TCR1045 Thy1.1+/− cells (D20), and 6 days following second infusion of TCR1045 Thy1.1+/+ cells (D26).
(C) Preferential accumulation and phenotype of second TCR1045 infusion in PDA (gated on CD8+Thy1.1+ cells). Concurrent PD1 expression on donor T cells from first (blue lines) and second (red lines) infusions. Grey histograms represent endogenous CD8+Thy1.1− T cells.
(D) Ratio of persisting cells 8 days after second infusion. dLN, draining lymph node; Thy, thymus; SG, salivary gland.
(E) Cytokine production by donor T cells at day 28 (see (A)). Cells were stimulated together and plots gated on CD8+ Thy1.1+/− (1st infusion) or CD8+ Thy1.1+/+ cells (2nd infusion).
Data are shown as mean ± SEM.